Patent details

Basic Information

Publication number:

EP2213285

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP091772004

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases

French Title of Invention:

Utilisation d'agonistes du récepteur de sphingosine-1-phosphate (S1P) en combinaison avec un deuxième principe actif pour le traitement de maladies dégénératives des fonctions cérébrales.

German Title of Invention:

Verwendung von Sphingosin-1-phosphat (S1P) Rezeptor-Agonisten in Kombination mit einem zweiten Mittel zur Behandlung von degenerativen Gehirnerkrankungen

SPC Number:

Dates

Filing date:

17/12/2004

Grant date:

06/11/2013

EP Publication Date:

06/11/2013

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

04/08/2010

EP B1 Publication Date:

06/11/2013

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

17/12/2013

Expiration date:

17/12/2024

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

17/12/2004

 

 

Name:

Novartis AG

Address:

Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Name:

Novartis Pharma GmbH

Address:

Brunner Strasse 59, 1230 Wien, Austria (AT)

Inventor

1

Name:

Kaneider Nicole

Address:

Austria (AT)

2

Name:

Wiedermann Christian J.

Address:

Austria (AT)

3

Name:

Brinkmann Volker

Address:

Germany (DE)

Priority

Priority Number:

0329498

Priority Date:

19/12/2003

Priority Country:

United Kingdom (GB)

Classification

Main IPC Class:

A61K 31/133;

Filing date	Document type	Number of pages